MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41409-024-02480-3

Медицинская библиотека · Bone marrow transplantation · 2024

A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study.

Zhou Jian-Ying, Chen Yu-Xiu, Yuan Hai-Long, Xu Ya-Jing, Huang Xiao-Bing, Gao Su-Jun, Zhang Yi-Cheng, Zhou Fang, Song Xian-Min, Luo Yi, Yang Jian-Min, Li Yu-Hua, Wang Shun-Qing, Dong Yu-Jun, Zhang Xi, Feng Yi-Mei, Du Xin, Zhu Han, Zhu Zun-Min, Bi Ke-Hong, Jiang Ming, Niu Ting, Wan Ding-Ming, Chen Yi, Liu Li, Yi Hai, Chen Yu-Hong, Wang Feng-Rong, Zhang Yuan-Yuan, Mo Xiao-Dong, Han Wei, Wang Jing-Zhi, Wang Yu, Chen Huan, Zhao Xiang-Yu, Chang Ying-Jun, Liu Kai-Yan, Huang Xiao-Jun, Zhang Xiao-Hui

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy and the only curable therapy is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, allo-HSCT is not appropriate for all CMML patients, and relapse is the leading cause of treatment failure. This project conducted a nationwide multicenter real-world study to develop a novel prediction scoring system for early relapse. A total of 238 CMML patients from twenty-seven medical centers treated with allo-HSCT, and 307 adult patients with CMML who underwent allo-HSCT in a publicly available research dataset from the Center for International Blood and Marrow Transplantation Registry (CIBMTR) database were included. Independent prognostic factors for the early relapse of CMML posttransplantation were identified according to competing risk regression methods. Four prognostic factors were identified: bone marrow blasts >10% (hazard ratio [HR], 4.262; P = 0.014), age >60 years (HR, 6.221; P = 0.007), hemoglobin level <100 g/L (HR, 3.695; P = 0.004), and non TET2 gene mutation (HR, 3.425; P = 0.017). A risk-grading scoring system was developed based on the regression coefficients and patients were stratified into low-risk (0-1 point), intermediate-risk (1.5-2 points) and high-risk ( > 2 points) groups. The validated internal c-statistic was 0.767 (95% confidence interval [CI], 0.674-0.860), and the external c-statistic was 0.769 (95% CI, 0.703-0.836). In the derivation cohort, the cumulative incidence rates of early relapse in the low-risk, intermediate-risk, and high-risk groups were 1.35% (95% CI: 1-4%), 10.40% (95% CI: 4-16%), and 29.54% (95% CI: 16-39%) (P < 0.001), respectively. This scoring system can be utilized to early identification of patients at a high risk of relapse and contributing to the implementation of urgent medical support.

Для цитирования: Zhou Jian-Ying, Chen Yu-Xiu, Yuan Hai-Long, Xu Ya-Jing, Huang Xiao-Bing, Gao Su-Jun, Zhang Yi-Cheng, Zhou Fang, Song Xian-Min, Luo Yi, Yang Jian-Min, Li Yu-Hua, Wang Shun-Qing, Dong Yu-Jun, Zhang Xi, Feng Yi-Mei, Du Xin, Zhu Han, Zhu Zun-Min, Bi Ke-Hong, Jiang Ming, Niu Ting, Wan Ding-Ming, Chen Yi, Liu Li, Yi Hai, Chen Yu-Hong, Wang Feng-Rong, Zhang Yuan-Yuan, Mo Xiao-Dong, Han Wei, Wang Jing-Zhi, Wang Yu, Chen Huan, Zhao Xiang-Yu, Chang Ying-Jun, Liu Kai-Yan, Huang Xiao-Jun, Zhang Xiao-Hui. A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study.. Bone marrow transplantation. 2024. DOI: 10.1038/s41409-024-02480-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.